{"id": "article-35868_0", "title": "Glycopyrrolate -- Continuing Education Activity", "content": "Glycopyrrolate, also known as glycopyrronium, is an anticholinergic drug. Glycopyrrolate has been widely used as a preoperative medication to inhibit salivary gland and respiratory secretions. The most frequent reasons for administering anticholinergics include producing an antisialagogue effect, creating a sedative and amnesic effect, and preventing reflex bradycardia. Glycopyrrolate is among the more common anticholinergic medications. It is used perioperatively as a muscarinic receptor antagonist. This activity outlines the indications, mechanism of action, dosing, important adverse effects, contraindications, monitoring, the toxicity of glycopyrrolate. It increases practitioners' knowledge regarding how to approach and use this medication and monitor it effectively to drive better patient outcomes.", "contents": "Glycopyrrolate -- Continuing Education Activity. Glycopyrrolate, also known as glycopyrronium, is an anticholinergic drug. Glycopyrrolate has been widely used as a preoperative medication to inhibit salivary gland and respiratory secretions. The most frequent reasons for administering anticholinergics include producing an antisialagogue effect, creating a sedative and amnesic effect, and preventing reflex bradycardia. Glycopyrrolate is among the more common anticholinergic medications. It is used perioperatively as a muscarinic receptor antagonist. This activity outlines the indications, mechanism of action, dosing, important adverse effects, contraindications, monitoring, the toxicity of glycopyrrolate. It increases practitioners' knowledge regarding how to approach and use this medication and monitor it effectively to drive better patient outcomes."}
{"id": "article-35868_1", "title": "Glycopyrrolate -- Continuing Education Activity", "content": "Objectives: Explain the mechanism of action of glycopyrrolate. Identify the indications for using glycopyrrolate on a patient. Review the necessary monitoring that must take place when utilizing glycopyrrolate. Outline interprofessional team strategies for improving care coordination and communication to advance improved outcomes using glycopyrrolate when indicated. Access free multiple choice questions on this topic.", "contents": "Glycopyrrolate -- Continuing Education Activity. Objectives: Explain the mechanism of action of glycopyrrolate. Identify the indications for using glycopyrrolate on a patient. Review the necessary monitoring that must take place when utilizing glycopyrrolate. Outline interprofessional team strategies for improving care coordination and communication to advance improved outcomes using glycopyrrolate when indicated. Access free multiple choice questions on this topic."}
{"id": "article-35868_2", "title": "Glycopyrrolate -- Indications", "content": "Glycopyrrolate, also known as glycopyrronium,\u00a0is an\u00a0anticholinergic drug. It is a synthetically created quaternary amine with pyridine and a cyclopentane moiety within the compound's structure. Glycopyrrolate\u00a0has been widely used as a preoperative medication to inhibit salivary gland and respiratory secretions. The most frequent reasons for administering anticholinergics\u00a0include producing an antisialagogue effect, creating a sedative and amnesic effect, and preventing reflex bradycardia. Anticholinergics are not predictably effective in increasing gastric fluid pH or decreasing gastric fluid volume. Glycopyrrolate is\u00a0among the most commonly used anticholinergic medications.", "contents": "Glycopyrrolate -- Indications. Glycopyrrolate, also known as glycopyrronium,\u00a0is an\u00a0anticholinergic drug. It is a synthetically created quaternary amine with pyridine and a cyclopentane moiety within the compound's structure. Glycopyrrolate\u00a0has been widely used as a preoperative medication to inhibit salivary gland and respiratory secretions. The most frequent reasons for administering anticholinergics\u00a0include producing an antisialagogue effect, creating a sedative and amnesic effect, and preventing reflex bradycardia. Anticholinergics are not predictably effective in increasing gastric fluid pH or decreasing gastric fluid volume. Glycopyrrolate is\u00a0among the most commonly used anticholinergic medications."}
{"id": "article-35868_3", "title": "Glycopyrrolate -- Indications", "content": "It is used perioperatively as a muscarinic receptor antagonist. [1] [2] The topical formulation of glycopyrrolate is indicated to treat primary axillary hyperhidrosis in nine and older patients. [3] It is also helpful to reduce severe or chronic drooling in pediatric patients with neurologic conditions, such as cerebral palsy.\u00a0The\u00a0intravenous formulation\u00a0of glycopyrrolate classically works to reverse vagal reflexes and bradycardia intraoperatively and reverse the\u00a0muscarinic effects of cholinergic agents such as neostigmine or pyridostigmine. [4] Glycopyrrolate\u00a0may be administered to reverse the neuromuscular blockade due to nondepolarizing muscle relaxants postoperatively and is frequently used in conjunction\u00a0with neostigmine, a cholinesterase inhibitor. [5] Various oral inhalation formulations of glycopyrrolate are indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). [6] [7]", "contents": "Glycopyrrolate -- Indications. It is used perioperatively as a muscarinic receptor antagonist. [1] [2] The topical formulation of glycopyrrolate is indicated to treat primary axillary hyperhidrosis in nine and older patients. [3] It is also helpful to reduce severe or chronic drooling in pediatric patients with neurologic conditions, such as cerebral palsy.\u00a0The\u00a0intravenous formulation\u00a0of glycopyrrolate classically works to reverse vagal reflexes and bradycardia intraoperatively and reverse the\u00a0muscarinic effects of cholinergic agents such as neostigmine or pyridostigmine. [4] Glycopyrrolate\u00a0may be administered to reverse the neuromuscular blockade due to nondepolarizing muscle relaxants postoperatively and is frequently used in conjunction\u00a0with neostigmine, a cholinesterase inhibitor. [5] Various oral inhalation formulations of glycopyrrolate are indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). [6] [7]"}
{"id": "article-35868_4", "title": "Glycopyrrolate -- Indications", "content": "Other commonly used anticholinergics include atropine and scopolamine. Most frequently, clinicians use glycopyrrolate to reduce pharyngeal, tracheal, bronchial, and sialagogue effects preoperatively;\u00a0decreased secretions are the desired effect during anesthesia when a tracheal tube is in place. A blockade of reflexive vagal cardiac inhibition reflexes during intubation and anesthetic induction may also occur.", "contents": "Glycopyrrolate -- Indications. Other commonly used anticholinergics include atropine and scopolamine. Most frequently, clinicians use glycopyrrolate to reduce pharyngeal, tracheal, bronchial, and sialagogue effects preoperatively;\u00a0decreased secretions are the desired effect during anesthesia when a tracheal tube is in place. A blockade of reflexive vagal cardiac inhibition reflexes during intubation and anesthetic induction may also occur."}
{"id": "article-35868_5", "title": "Glycopyrrolate -- Mechanism of Action", "content": "Glycopyrrolate's primary mechanism of action is the blockage of acetylcholine's effects at the parasympathetic sites in various tissues. This blockage primarily occurs in the central nervous system, smooth muscle, and secretory glands. It also reduces the rate of salivation by preventing the stimulation of the acetylcholine receptors themselves. Glycopyrrolate does not cross the blood-brain barrier or the placenta. It has a slower diffusion rate relative to other anticholinergic drugs such as atropine\u00a0and scopolamine. [8] [9]", "contents": "Glycopyrrolate -- Mechanism of Action. Glycopyrrolate's primary mechanism of action is the blockage of acetylcholine's effects at the parasympathetic sites in various tissues. This blockage primarily occurs in the central nervous system, smooth muscle, and secretory glands. It also reduces the rate of salivation by preventing the stimulation of the acetylcholine receptors themselves. Glycopyrrolate does not cross the blood-brain barrier or the placenta. It has a slower diffusion rate relative to other anticholinergic drugs such as atropine\u00a0and scopolamine. [8] [9]"}
{"id": "article-35868_6", "title": "Glycopyrrolate -- Mechanism of Action -- Pharmacokinetics", "content": "Glycopyrrolate exhibits onset of action within 1 minute when given intravenously and an elimination half-life of approximately 50 minutes. Glycopyrrolate undergoes urinary excretion and elimination. It differs from atropine in being a quaternary amine and has both cyclopentane and pyridine moieties in the compound. [10] Glycopyrrolate has a 2 to the 4-hour duration of action after intravenous administration, while atropine has 30 minutes.", "contents": "Glycopyrrolate -- Mechanism of Action -- Pharmacokinetics. Glycopyrrolate exhibits onset of action within 1 minute when given intravenously and an elimination half-life of approximately 50 minutes. Glycopyrrolate undergoes urinary excretion and elimination. It differs from atropine in being a quaternary amine and has both cyclopentane and pyridine moieties in the compound. [10] Glycopyrrolate has a 2 to the 4-hour duration of action after intravenous administration, while atropine has 30 minutes."}
{"id": "article-35868_7", "title": "Glycopyrrolate -- Administration", "content": "Glycopyrrolate administration can be intravenous, intramuscular, oral, or topical.", "contents": "Glycopyrrolate -- Administration. Glycopyrrolate administration can be intravenous, intramuscular, oral, or topical."}
{"id": "article-35868_8", "title": "Glycopyrrolate -- Administration", "content": "Glycopyrrolate for injection comes packaged as a solution of 0.2 mg/mL. Before intravenous administration, inspect the syringe to ensure no particulate matter. Intramuscular or intravenous administration requires no dilution and should be at 0.2 mg over 1 to 2 minutes. Additionally, it may be administered via the tubing of a running intravenous infusion of a compatible solution. [11] Storage of the drug should be in a cool, dry area protected from light before administration. Promptly discard unused solution as it is unstable at a pH greater than 6. The typical dose of glycopyrrolate is one-half that of atropine. For instance, the premedication dose is 0.005 to 0.01 mg/kg up to 0.2 to 0.3 mg in adults.", "contents": "Glycopyrrolate -- Administration. Glycopyrrolate for injection comes packaged as a solution of 0.2 mg/mL. Before intravenous administration, inspect the syringe to ensure no particulate matter. Intramuscular or intravenous administration requires no dilution and should be at 0.2 mg over 1 to 2 minutes. Additionally, it may be administered via the tubing of a running intravenous infusion of a compatible solution. [11] Storage of the drug should be in a cool, dry area protected from light before administration. Promptly discard unused solution as it is unstable at a pH greater than 6. The typical dose of glycopyrrolate is one-half that of atropine. For instance, the premedication dose is 0.005 to 0.01 mg/kg up to 0.2 to 0.3 mg in adults."}
{"id": "article-35868_9", "title": "Glycopyrrolate -- Administration", "content": "Oral tablets are available in 1 mg, 1.5 mg, and 2 mg strength and oral solution is available in 1mg/5mL strength. The starting dose is 1 to 2 mg twice a day and titrated upward gradually based on patient response to the treatment. [12]", "contents": "Glycopyrrolate -- Administration. Oral tablets are available in 1 mg, 1.5 mg, and 2 mg strength and oral solution is available in 1mg/5mL strength. The starting dose is 1 to 2 mg twice a day and titrated upward gradually based on patient response to the treatment. [12]"}
{"id": "article-35868_10", "title": "Glycopyrrolate -- Administration", "content": "The topical formulation is available as a single-use cloth pre-moistened with a 2.4% glycopyrronium solution. It is used no more than once every 24 hours on both underarms. [13]", "contents": "Glycopyrrolate -- Administration. The topical formulation is available as a single-use cloth pre-moistened with a 2.4% glycopyrronium solution. It is used no more than once every 24 hours on both underarms. [13]"}
{"id": "article-35868_11", "title": "Glycopyrrolate -- Administration", "content": "Inhalation formulation available as the dry powder inhaler 15.6 mcg capsule twice daily and as the nebulization solution of one 25 mcg vial inhaled twice daily. [14]", "contents": "Glycopyrrolate -- Administration. Inhalation formulation available as the dry powder inhaler 15.6 mcg capsule twice daily and as the nebulization solution of one 25 mcg vial inhaled twice daily. [14]"}
{"id": "article-35868_12", "title": "Glycopyrrolate -- Administration -- Specific Patient Population", "content": "Pregnancy Considerations: Glycopyrrolate in usual doses does not influence fetal heart rate or fetal heart rate variability to a significant extent. After parenteral administration, there\u00a0is\u00a0a low concentration of glycopyrrolate in umbilical venous and arterial blood and the amniotic fluid. Glycopyrrolate does not seem to penetrate through the placental barrier significantly. As animal reproduction studies are not consistently predictive of human response, this drug should be used during pregnancy only if needed. In general, because of limited data in human pregnancy studies, both atropine and glycopyrrolate are considered acceptable anticholinergics, and usage varies based on the clinician's preference. [15]", "contents": "Glycopyrrolate -- Administration -- Specific Patient Population. Pregnancy Considerations: Glycopyrrolate in usual doses does not influence fetal heart rate or fetal heart rate variability to a significant extent. After parenteral administration, there\u00a0is\u00a0a low concentration of glycopyrrolate in umbilical venous and arterial blood and the amniotic fluid. Glycopyrrolate does not seem to penetrate through the placental barrier significantly. As animal reproduction studies are not consistently predictive of human response, this drug should be used during pregnancy only if needed. In general, because of limited data in human pregnancy studies, both atropine and glycopyrrolate are considered acceptable anticholinergics, and usage varies based on the clinician's preference. [15]"}
{"id": "article-35868_13", "title": "Glycopyrrolate -- Administration -- Specific Patient Population", "content": "Breastfeeding Considerations: Glycopyrrolate is a quaternary ammonium compound; it is not likely to be absorbed and reach the infant's bloodstream, particularly when given by inhalation or applied topically on the skin. Long-term oral use of glycopyrrolate might reduce milk production or milk letdown, but a single dose is unlikely to interfere with breastfeeding. Observe for signs of decreased lactation (e.g., insatiety, poor weight gain). [10] Patients with Renal Impairment: According to product labeling, dose adjustment might be necessary. Clinicain should exercise caution when using glycopyrrolate in patients with renal impairment. Patients with Hepatic Impairment: According to product labeling, information on patients with hepatic impairment is unavailable. Use with caution. Pediatrics Patients: Usage should generally\u00a0be avoided in neonates. A\u00a0hyperexcitability reaction can potentially occur with higher than recommended dosages; use with caution.", "contents": "Glycopyrrolate -- Administration -- Specific Patient Population. Breastfeeding Considerations: Glycopyrrolate is a quaternary ammonium compound; it is not likely to be absorbed and reach the infant's bloodstream, particularly when given by inhalation or applied topically on the skin. Long-term oral use of glycopyrrolate might reduce milk production or milk letdown, but a single dose is unlikely to interfere with breastfeeding. Observe for signs of decreased lactation (e.g., insatiety, poor weight gain). [10] Patients with Renal Impairment: According to product labeling, dose adjustment might be necessary. Clinicain should exercise caution when using glycopyrrolate in patients with renal impairment. Patients with Hepatic Impairment: According to product labeling, information on patients with hepatic impairment is unavailable. Use with caution. Pediatrics Patients: Usage should generally\u00a0be avoided in neonates. A\u00a0hyperexcitability reaction can potentially occur with higher than recommended dosages; use with caution."}
{"id": "article-35868_14", "title": "Glycopyrrolate -- Adverse Effects", "content": "Adverse reactions after glycopyrrolate administration may include anticholinergic symptoms such as mydriasis, hyperthermia, tachycardia, and cardiac arrhythmia. They may also include blurred vision, constipation, cycloplegia, dry mouth, dry skin, flushing, photophobia, urinary retention, and xerophthalmia. [2] [16]", "contents": "Glycopyrrolate -- Adverse Effects. Adverse reactions after glycopyrrolate administration may include anticholinergic symptoms such as mydriasis, hyperthermia, tachycardia, and cardiac arrhythmia. They may also include blurred vision, constipation, cycloplegia, dry mouth, dry skin, flushing, photophobia, urinary retention, and xerophthalmia. [2] [16]"}
{"id": "article-35868_15", "title": "Glycopyrrolate -- Adverse Effects", "content": "Glycopyrrolate may affect the patient's ability to perform tasks requiring mental alertness. In addition, the medication may induce drowsiness\u00a0or blurred vision, which is exacerbated by the consumption of alcohol. Usage also requires close monitoring in patients with hepatic impairment. For example, patients may not be able to\u00a0operate heavy machinery safely.", "contents": "Glycopyrrolate -- Adverse Effects. Glycopyrrolate may affect the patient's ability to perform tasks requiring mental alertness. In addition, the medication may induce drowsiness\u00a0or blurred vision, which is exacerbated by the consumption of alcohol. Usage also requires close monitoring in patients with hepatic impairment. For example, patients may not be able to\u00a0operate heavy machinery safely."}
{"id": "article-35868_16", "title": "Glycopyrrolate -- Adverse Effects", "content": "Use with discretion\u00a0in patients with autonomic neuropathy or hyperthyroidism. Heat prostration can occur in the presence of fever, high ambient temperature, or physical exercise. Take caution to avoid this effect by limiting or discontinuing usage with exercise or in situations with elevated ambient temperatures. Patients under the age of 12 with pediatric spastic paralysis are more likely to exhibit an increased anticholinergic response, which elevates the risk for unwanted effects. [17]", "contents": "Glycopyrrolate -- Adverse Effects. Use with discretion\u00a0in patients with autonomic neuropathy or hyperthyroidism. Heat prostration can occur in the presence of fever, high ambient temperature, or physical exercise. Take caution to avoid this effect by limiting or discontinuing usage with exercise or in situations with elevated ambient temperatures. Patients under the age of 12 with pediatric spastic paralysis are more likely to exhibit an increased anticholinergic response, which elevates the risk for unwanted effects. [17]"}
{"id": "article-35868_17", "title": "Glycopyrrolate -- Contraindications", "content": "Glycopyrrolate is contraindicated in patients with hypersensitivity to glycopyrronium, excipients, or other ingredients in the anticholinergic class. The following is a list of medical conditions that would preclude the use of anticholinergic therapy, categorized by the system: Ophthalmic: angle-closure glaucoma [18] Cardiovascular: mitral stenosis and cardiovascular instability in acute hemorrhage [19] Gastrointestinal: hiatal hernia, gastrointestinal obstruction, paralytic ileus, reflux esophagitis, severe ulcerative colitis, toxic megacolon, intestinal atony in elderly or debilitated patients [20] [21] Neuromuscular: myasthenia gravis [22] Urologic: obstructive uropathy [23] Using solid oral formulations of potassium chloride needs close monitoring if considering coadministration with glycopyrrolate. [24]", "contents": "Glycopyrrolate -- Contraindications. Glycopyrrolate is contraindicated in patients with hypersensitivity to glycopyrronium, excipients, or other ingredients in the anticholinergic class. The following is a list of medical conditions that would preclude the use of anticholinergic therapy, categorized by the system: Ophthalmic: angle-closure glaucoma [18] Cardiovascular: mitral stenosis and cardiovascular instability in acute hemorrhage [19] Gastrointestinal: hiatal hernia, gastrointestinal obstruction, paralytic ileus, reflux esophagitis, severe ulcerative colitis, toxic megacolon, intestinal atony in elderly or debilitated patients [20] [21] Neuromuscular: myasthenia gravis [22] Urologic: obstructive uropathy [23] Using solid oral formulations of potassium chloride needs close monitoring if considering coadministration with glycopyrrolate. [24]"}
{"id": "article-35868_18", "title": "Glycopyrrolate -- Monitoring", "content": "Glycopyrronium reduces the body's ability to sweat. Therefore,\u00a0it\u00a0may cause hyperthermia\u00a0and heat stroke\u00a0in hot environments. Other observed adverse effects include dry mouth, difficulty urinating, headaches, diarrhea, and constipation.\u00a0Monitor heart rate and maintain adequate hydration to avoid adverse events.", "contents": "Glycopyrrolate -- Monitoring. Glycopyrronium reduces the body's ability to sweat. Therefore,\u00a0it\u00a0may cause hyperthermia\u00a0and heat stroke\u00a0in hot environments. Other observed adverse effects include dry mouth, difficulty urinating, headaches, diarrhea, and constipation.\u00a0Monitor heart rate and maintain adequate hydration to avoid adverse events."}
{"id": "article-35868_19", "title": "Glycopyrrolate -- Monitoring", "content": "A dose adjustment may be necessary if urinary retention occurs. Existing renal impairment may be further complicated. In the general population, usage may increase the risk of confusion, hallucinations, and anticholinergic effects. [25]", "contents": "Glycopyrrolate -- Monitoring. A dose adjustment may be necessary if urinary retention occurs. Existing renal impairment may be further complicated. In the general population, usage may increase the risk of confusion, hallucinations, and anticholinergic effects. [25]"}
{"id": "article-35868_20", "title": "Glycopyrrolate -- Monitoring", "content": "Use glycopyrrolate with caution in patients with a hiatal hernia\u00a0and reflux esophagitis. It can worsen prostatic hyperplasia symptoms and/or bladder neck destruction as it may increase urinary retention.\u00a0In ulcerative colitis cases, a high dose may inhibit intestinal motility and\u00a0worsen toxic megacolon or ileus symptoms. Glycopyrrolate administration\u00a0is contraindicated in patients with ulcerative colitis. Since gastrointestinal motility may decline, constipation or intestinal pseudo-obstruction may occur. If the latter condition arises, it may result in pain from abdominal distention, nausea, or vomiting. If intestinal\u00a0obstruction of any type is suspected, it is imperative to\u00a0discontinue use and simultaneously reevaluate. Symptoms presenting as diarrhea, particularly in patients who have undergone bowel resections of the ileum or colon, warrant a lower threshold for clinical suspicion. When an\u00a0obstruction is suspected, or if the patient has\u00a0diarrhea, promptly discontinue treatment. [11]", "contents": "Glycopyrrolate -- Monitoring. Use glycopyrrolate with caution in patients with a hiatal hernia\u00a0and reflux esophagitis. It can worsen prostatic hyperplasia symptoms and/or bladder neck destruction as it may increase urinary retention.\u00a0In ulcerative colitis cases, a high dose may inhibit intestinal motility and\u00a0worsen toxic megacolon or ileus symptoms. Glycopyrrolate administration\u00a0is contraindicated in patients with ulcerative colitis. Since gastrointestinal motility may decline, constipation or intestinal pseudo-obstruction may occur. If the latter condition arises, it may result in pain from abdominal distention, nausea, or vomiting. If intestinal\u00a0obstruction of any type is suspected, it is imperative to\u00a0discontinue use and simultaneously reevaluate. Symptoms presenting as diarrhea, particularly in patients who have undergone bowel resections of the ileum or colon, warrant a lower threshold for clinical suspicion. When an\u00a0obstruction is suspected, or if the patient has\u00a0diarrhea, promptly discontinue treatment. [11]"}
{"id": "article-35868_21", "title": "Glycopyrrolate -- Monitoring", "content": "Because of its quaternary structure, glycopyrrolate cannot cross the blood-brain barrier and is almost devoid of the central nervous system and ophthalmic activity. Potent inhibition of salivary gland and respiratory tract secretions is the primary rationale for using glycopyrrolate as a premedication. Heart rate usually increases after intravenous\u00a0administration but not intramuscular. [2]", "contents": "Glycopyrrolate -- Monitoring. Because of its quaternary structure, glycopyrrolate cannot cross the blood-brain barrier and is almost devoid of the central nervous system and ophthalmic activity. Potent inhibition of salivary gland and respiratory tract secretions is the primary rationale for using glycopyrrolate as a premedication. Heart rate usually increases after intravenous\u00a0administration but not intramuscular. [2]"}
{"id": "article-35868_22", "title": "Glycopyrrolate -- Toxicity", "content": "Acute toxicity with glycopyrrolate is secondary to an extension of the pharmacologic effects on the muscarinic cholinergic receptors. Muscarinic receptor sites are located in the brain's cerebral cortex, thalamus, hippocampus, and reticular activating system. They are also present in the postganglionic parasympathetic nervous system and other sites like sweat glands. Anticholinergic agents block the effects of acetylcholine by competitively binding and blocking muscarinic receptors.", "contents": "Glycopyrrolate -- Toxicity. Acute toxicity with glycopyrrolate is secondary to an extension of the pharmacologic effects on the muscarinic cholinergic receptors. Muscarinic receptor sites are located in the brain's cerebral cortex, thalamus, hippocampus, and reticular activating system. They are also present in the postganglionic parasympathetic nervous system and other sites like sweat glands. Anticholinergic agents block the effects of acetylcholine by competitively binding and blocking muscarinic receptors."}
{"id": "article-35868_23", "title": "Glycopyrrolate -- Toxicity -- Central Nervous System Toxicity", "content": "CNS toxicity is also called a central anticholinergic syndrome, as central nervous system toxicity can be an undesirable side effect of any anticholinergic medication. It manifests as delirium or prolonged somnolence after anesthesia. While this is more likely to occur with scopolamine than atropine, the incidence should be low with the administration of proper dosages. However, elderly patients may be uniquely susceptible. Glycopyrrolate is less likely to cause this condition than other anticholinergic medications because it does not cross the blood-brain barrier. [26]", "contents": "Glycopyrrolate -- Toxicity -- Central Nervous System Toxicity. CNS toxicity is also called a central anticholinergic syndrome, as central nervous system toxicity can be an undesirable side effect of any anticholinergic medication. It manifests as delirium or prolonged somnolence after anesthesia. While this is more likely to occur with scopolamine than atropine, the incidence should be low with the administration of proper dosages. However, elderly patients may be uniquely susceptible. Glycopyrrolate is less likely to cause this condition than other anticholinergic medications because it does not cross the blood-brain barrier. [26]"}
{"id": "article-35868_24", "title": "Glycopyrrolate -- Toxicity -- Tachycardia", "content": "The most likely response after intramuscular administration of atropine, glycopyrrolate, or scopolamine for premedication is an increase in heart rate, indicating a weak cholinergic antagonist effect of these drugs.", "contents": "Glycopyrrolate -- Toxicity -- Tachycardia. The most likely response after intramuscular administration of atropine, glycopyrrolate, or scopolamine for premedication is an increase in heart rate, indicating a weak cholinergic antagonist effect of these drugs."}
{"id": "article-35868_25", "title": "Glycopyrrolate -- Toxicity -- Treatment", "content": "According to product labeling, a quaternary ammonium anticholinesterase such as neostigmine (which does not cross the blood-brain barrier) can be given to combat peripheral anticholinergic effects parenterally in increments of 0.25 mg in adults. It may be repeated every five to ten minutes until anticholinergic overactivity is reversed or up to a maximum of 2.5 mg.\u00a0If CNS symptoms (e.g., restlessness, excitement, psychotic behavior, convulsions) are present, physostigmine (which does cross the blood-brain barrier) should be administered. Physostigmine 0.5 to 2 mg can be administered intravenously and repeated up to 5 mg in adults. To combat hypotension, administer IV fluids and pressor agents and supportive care.", "contents": "Glycopyrrolate -- Toxicity -- Treatment. According to product labeling, a quaternary ammonium anticholinesterase such as neostigmine (which does not cross the blood-brain barrier) can be given to combat peripheral anticholinergic effects parenterally in increments of 0.25 mg in adults. It may be repeated every five to ten minutes until anticholinergic overactivity is reversed or up to a maximum of 2.5 mg.\u00a0If CNS symptoms (e.g., restlessness, excitement, psychotic behavior, convulsions) are present, physostigmine (which does cross the blood-brain barrier) should be administered. Physostigmine 0.5 to 2 mg can be administered intravenously and repeated up to 5 mg in adults. To combat hypotension, administer IV fluids and pressor agents and supportive care."}
{"id": "article-35868_26", "title": "Glycopyrrolate -- Enhancing Healthcare Team Outcomes", "content": "Glycopyrrolate is a frequently prescribed agent by the nurse practitioner, primary care provider, anesthesiologist, and internist. However, all healthcare workers who prescribe this agent should be aware of its potential adverse effects.\u00a0Glycopyrronium may cause hyperthermia\u00a0and heat stroke\u00a0in hot environments as it reduces the body's ability to sweat. Clinicians should monitor liver function tests in patients with hepatic impairment. Nursing staff should monitor and inform the prescriber if urinary retention occurs and existing renal impairment worsens. The use\u00a0of glycopyrrolate in the general population may increase the risk\u00a0of\u00a0confusion, hallucinations, and other anticholinergic effects. [25] Before administering glycopyrrolate therapy, nurses should counsel patients for common adverse effects\u00a0like dry mouth, difficulty urinating, headaches, diarrhea, and constipation. Pharmacists should verify the dose and possible drug-disease interactions. Pharmacists should warn the patient that the medication may induce drowsiness\u00a0or blurred vision, which is exacerbated by alcohol consumption. As health care team members, all MDs, DOs, PAs, NPs, nursing staff, and pharmacists should collaborate to improve care coordination and communicate to advance better outcomes using glycopyrrolate when indicated.", "contents": "Glycopyrrolate -- Enhancing Healthcare Team Outcomes. Glycopyrrolate is a frequently prescribed agent by the nurse practitioner, primary care provider, anesthesiologist, and internist. However, all healthcare workers who prescribe this agent should be aware of its potential adverse effects.\u00a0Glycopyrronium may cause hyperthermia\u00a0and heat stroke\u00a0in hot environments as it reduces the body's ability to sweat. Clinicians should monitor liver function tests in patients with hepatic impairment. Nursing staff should monitor and inform the prescriber if urinary retention occurs and existing renal impairment worsens. The use\u00a0of glycopyrrolate in the general population may increase the risk\u00a0of\u00a0confusion, hallucinations, and other anticholinergic effects. [25] Before administering glycopyrrolate therapy, nurses should counsel patients for common adverse effects\u00a0like dry mouth, difficulty urinating, headaches, diarrhea, and constipation. Pharmacists should verify the dose and possible drug-disease interactions. Pharmacists should warn the patient that the medication may induce drowsiness\u00a0or blurred vision, which is exacerbated by alcohol consumption. As health care team members, all MDs, DOs, PAs, NPs, nursing staff, and pharmacists should collaborate to improve care coordination and communicate to advance better outcomes using glycopyrrolate when indicated."}
{"id": "article-35868_27", "title": "Glycopyrrolate -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Glycopyrrolate -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}